Normal antibody response after COVID-19 during treatment with cladribine.
Normal antibody response after COVID-19 during treatment with cladribine.
复制标题
DOI：
10.1016/j.msard.2020.102476
复制
发表时间：
2020-11
影响因子：
4
通讯作者：
Celius EG
中科院分区：
文献类型：
--
作者：
Celius EG
克拉屈滨是一种非常有效的，最近可用的治疗多发性硬化症。本病例报告描述了1例在克拉屈滨治疗第二年期间发生轻度COVID-19感染的患者。感染后三个月，免疫反应正常，可检测到SARS-CoV 2抗体。克拉屈滨是一种非常有效的，最近可用的治疗多发性硬化症。本病例报告描述了一名在克拉屈滨治疗第二年期间感染COVID-19的患者。感染是轻微的，三个月后她能够通过可检测的抗体产生足够的免疫反应。
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with a mild COVID-19 infection during second year treatment with cladribine. Normal immune response with detectable antibodies to SARS-CoV2 three months after the infection. Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.
登录
查看更多内容
影响因子：
4
作者：
Cook, Stuart;Leist, Thomas;Sylvester, Elke
通讯作者：
Sylvester, Elke
影响因子：
5.9
作者：
Patti, Francesco;Visconti, Andrea;Trojano, Maria
通讯作者：
Trojano, Maria
影响因子：
29
作者：
Luna, Gustavo;Alping, Peter;Frisell, Thomas
通讯作者：
Frisell, Thomas
影响因子：
4
作者：
Comi, Giancarlo;Cook, Stuart;Dangond, Fernando
通讯作者：
Dangond, Fernando